Anti-CD40 Antibodies and Methods of Use - Apexigen
Summary
The European Patent Office published patent EP3508500A1 granting Apexigen, Inc. exclusive rights to anti-CD40 antibody compositions and therapeutic methods. The patent covers C07K 16/28 antibodies targeting CD40 for treatment of oncology indications including A61P 35/00. Protection extends across 31 designated European Contracting States including Germany, France, UK, Italy, Spain, and the Netherlands.
What changed
EPO granted patent EP3508500A1 to Apexigen, Inc. covering anti-CD40 monoclonal antibodies and methods of using such antibodies for therapeutic applications, particularly in cancer treatment. The patent claims priority to earlier applications and names three inventors: Zhang Yongke, Yu Guo-Liang, and Zhu Weimin. Designated states include all major European markets.
For biotech and pharmaceutical companies developing CD40 agonist or antagonist therapies, this patent establishes a potential blocking position in the European market. Companies should conduct freedom-to-operate analyses and consider design-around strategies or licensing negotiations with Apexigen before advancing CD40-targeted drug candidates toward clinical development or commercialization in Europe.
What to do next
- Review patent claims for freedom-to-operate if developing CD40-targeted therapeutics
- Monitor patent family for related applications in key markets including US, Japan, and China
- Assess licensing opportunities with Apexigen for CD40 antibody commercialization
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-CD40 ANTIBODIES AND METHODS OF USE
Publication EP3508500A1 Kind: A1 Apr 01, 2026
Applicants
Apexigen, Inc.
Inventors
ZHANG, Yongke, YU, Guo-Liang, ZHU, Weimin
IPC Classifications
C07K 16/28 20060101AFI20190606BHEP C12N 15/13 20060101ALI20190606BHEP A61K 39/395 20060101ALI20190606BHEP A61P 35/00 20060101ALI20190606BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.